Jacek Pinski, MD
Enriched profileAssociate Professor of Medicine (tenured), with GU Clinical Program Chair role, Division of Medical Oncology, Norris Comprehensive Cancer Center · University of Southern California (USC)
Jacek Pinski is Associate Professor of Medicine (tenured), with GU Clinical Program Chair role, Division of Medical Oncology, Norris Comprehensive Cancer Center at University of Southern California (USC). ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 22 Oct 2026
Overview
Updated 25 Oct 2026
Jacek Pinski, M.D., is Associate Professor of Medicine (tenured), with GU Clinical Program Chair role, Division of Medical Oncology, Norris Comprehensive Cancer Center at University of Southern California (USC), Keck School of Medicine. The public record shows 199 publications with 3,984 citations (h-index 34), centered on Prostate Cancer, Kidney Cancer / RCC, Kidney Neoplasms. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 30 companies, 4 NIH-funded awards (2003–2018).
- Top research focus: Prostate Cancer
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 30 companies
Generated from the cited public record · current as of 25 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 25 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
- Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Sponsor: National Cancer Institute (NCI)
- Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures
Sponsor: University of Southern California
Industry payments
Updated 25 Oct 2026
30 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202527 payments$25,223openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202529 payments$17,268openpaymentsdata.cms.gov ↗
- Sumitomo Pharma America, Inc.Program year202516 payments$10,946openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Genitourinary & hormones
51.5%5-alpha Reductase Inhibitor51.5%Finasteride100%Part D<11 patientsCancer & immunology
48.5%Anti-androgens48.5%Erleada100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 25 Oct 2026
4 NIH research awards on record, funded 2003–2018 per NIH RePORTER. The latest:
- Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
University of Southern California
FY2018$662,099R01CA172436 - Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
University of Southern California
FY2017$665,642R01CA172436 - Biomarkers of Hormone Therapy Response in a Multicenter Prostate Cancer Trial
University of Southern California
FY2016$669,388R01CA172436
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer
Prostate Cancer and Prostatic Diseases
2020 - Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types
Biochemical and Biophysical Research Communications
2018
Online presence
Updated 25 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jacek-pinski-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 25 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD1987verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancertrials.keckmedicine.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →integrativehealth.usc.edu ↗
- Board certified
American Board of Internal Medicine, Medical Oncology
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancertrials.keckmedicine.org ↗ - Board certified
American Board of Internal Medicine, Internal Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancertrials.keckmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Member
Rehabilitation Research and Development Section, United States Department of Veterans Affairs
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →internalmedicine.usc.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
USC/Norris Comprehensive Cancer Center Prostate Cancer Research Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →internalmedicine.usc.edu ↗ - verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancertrials.keckmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)